Previous 10 | Next 10 |
Gainers: Regional Health Properties (NYSE:RHE) +53%, AC Immune (NASDAQ:ACIU) +39%, Regencell Bioscience (NASDAQ:RGC) +29%, Qualigen Therapeutics (NASDAQ:QLGN) +19%, Reneo Pharmaceuticals (NASDAQ:RPHM) +17%. Losers: RenovoRx (NASDAQ:RNXT) -21%, ...
Gainers: NeuroMetrix (NASDAQ:NURO) +54%, Reneo Pharmaceuticals (NASDAQ:RPHM) +24%, Neoleukin Therapeutics (NASDAQ:NLTX) +21%, Chembio Diagnostics (NASDAQ:CEMI) +17%, InspireMD (NASDAQ:NSPR) +14%. Losers: Cassava Sciences (NASDAQ:SAVA) -28%, Applied Ther...
Today, we take a gander at a small biotech developmental company for the first time. The firm is well-funded, has multiple "shots on goal" and is aiming at some niche markets with no approved therapies. A full investment analysis follows in the paragraphs below. For further ...
IRVINE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, today reported financial results for th...
Reneo Pharmaceuticals (RPHM) announces that the first patient has been dosed in Phase 2b STRIDE study.The trial is designed to evaluate the efficacy and safety of REN001 for the treatment of patients with primary mitochondrial myopathies ((PMM)). REN001 100 mg will be administered orally, onc...
IRVINE, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the first patient h...
Reneo Pharmaceuticals (RPHM) has announced that the several underwriters of Reneo’s IPO, have agreed to waive the lock-up restriction with respect to 111,736 shares of common stock held by Wendy Johnson, who previously announced her intention to retire on or before Dec. 31, 2021.T...
SAN DIEGO, July 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, announced today that Jefferies LLC, SVB Leeri...
SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will provide a corp...
Reneo Pharmaceuticals (RPHM) has joined the broad-market Russell 3000 Index, effective after the market close on June 28, 2021. Membership in the U.S. all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Ru...
News, Short Squeeze, Breakout and More Instantly...
Reneo Pharmaceuticals Inc. Company Name:
RPHM Stock Symbol:
NASDAQ Market:
Reneo Pharmaceuticals Inc. Website:
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc. (NYSE:SQSP)'s sal...
MONSEY, N.Y., May 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the proposed merger of Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) (“Reneo”) with privately held OnKure, Inc. (“OnKure”) in a stock-for-stock transaction under which ...
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide fun...